Natasha Persaud

The perioperative period is receiving increased attention as a platform to inhibit cancer progression, according to investigators.

Study results suggest that tumor debulking does not provide benefit patients undergoing radical cystectomy.

Since FDA approval of imtainib, 40 newer tyrosine kinase inhibitor agents have been approved.

Among patients with a variety of solid tumors, investigators found favorable associations of immune checkpoint inhibitor therapy with quality of life compared with no immunotherapy use.

The neoadjuvant chemotherapy regimen may be especially effective against micrometastatic disease, investigators suggested.

An accurate estimate of future GFR after nephrectomy would help to guide operative strategy and use of adjuvant or neoadjuvant therapies, according to a recent editorial.

Investigators studied the effect of sequential valrubicin and docetaxel in patients with recurrent NMIBC following treatment with intravesical bacillus Calmette-Guérin and/or gemcitabine-docetaxel.

A novel scoring system could identify men at increased risk of death after prostatectomy who would benefit from adjuvant radiation therapy.

A report in the Journal of the National Cancer Institute presents findings from the first assessment of the real-world safety of abiraterone and enzalutamide in a national sample of Medicare beneficiaries with advanced prostate cancer.

Investigators report findings from the largest analysis characterizing objective imaging response among patients with mRCC treated in routine clinical practice.